Trial Profile
A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 27 Feb 2018 New trial record